NDAORALTABLET
Approved
Sep 1984
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
6/8 — Strong
ALLOPURINOL (allopurinol) by Teva is xanthine oxidase inhibitors [moa]. Approved for gout, tumor lysis syndrome, hyperuricemia. First approved in 1984.
Drug data last refreshed 20h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Allopurinol is an oral xanthine oxidase inhibitor tablet approved in 1984 for the treatment of leukemia and lymphoma. It works by inhibiting xanthine oxidase, an enzyme that catalyzes the production of uric acid, thereby reducing hyperuricemia associated with malignancy and chemotherapy. As a long-established generic drug, allopurinol remains a foundational agent in oncology supportive care, though it is now approaching loss of exclusivity with significant generic competition.
$0.0BPart D
Mechanism of Action
Xanthine Oxidase Inhibitors
Pharmacologic Class:
Xanthine Oxidase Inhibitor
Indications (3)
Worked on ALLOPURINOL at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.